News
Article
Author(s):
Following MDS 2021, we compiled a roundup of some of our discussions with experts in the Parkinson disease and movement disorders space in one convenient location.
The International Parkinson and Movement Disorders (MDS) Society Virtual Congress 2021, September 17-22, featured presentations from leaders and experts in the fields of Parkinson disease (PD) and movement disorders, outlining the latest advances in the field, as well as calling attention to areas and needs for future research.
Presentations covered a multitude of topics, including the efficacy of medical cannabis in treating dystonia, the potential of omavalexolone in treating Friedrich Ataxia, dance class interventions for patients with PD, as well as the impact of the COVID-19 pandemic on specific patient populations with movement disorders.
The NeurologyLive team spoke with experts over the course of the virtual event, diving deeper into key findings from individual studies—swipe through the slideshow to browse our interviews and to hear what experts are saying about PD and movement disorders.
The MOXIe trial (NCT02255435), featuring a 2-part study design, is the largest global interventional trial ever conducted in Friedrich Ataxia (FA). The study evaluated the efficacy and safety of omaveloxolone (Reata Pharmaceuticals) in a cohort of 73 patients with FA, using differences in modified Friedrich’s Ataxia Rating Scale (mFARS) scores as the primary end point.1
At MDS 2021, data from the open-label, delayed-start period of the MOXIe trial was presented by David R. Lynch, MD, PhD, professor of neurology, University of Pennsylvania Perelman School of Medicine. Lynch sat down with NeurologyLive to provide background on the results, including the notable topline findings and the substantial improvement in those who previously switched from placebo.
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.